期刊文献+

苯酰胺类c-Met激酶抑制剂的合成及其体外抗肿瘤活性研究 被引量:2

Synthesis of benzamide compounds c-Met inhibitors and its anti-tumor activities in vitro
原文传递
导出
摘要 目的设计和合成苯酰胺类c-Met激酶抑制剂,并测定其体外抗肿瘤活性。方法以4-氯-6,7二甲氧基喹啉、6-氯-7-氮杂嘌呤和4-氯-7-氮杂吲哚为起始物,经取代、还原和缩合反应制备目标化合物3a^5c,并采用噻唑蓝法(MTT)测定目标化合物对GTL-16细胞的抑制作用。结果合成了9个化合物,其结构经MS、1H-NMR和13C-NMR确证。化合物3a^5c对GTL-16细胞均呈现不同程度的抑制作用,其中化合物3c对GTL-16细胞的IC50达到411 nmol/L。结论苯酰胺类化合物具有抑制GTL-16细胞活性的作用,值得进一步深入研究。 Objective To design and synthesize benzamide compounds c-Met inhibitors, and study their anti-tumor activities in vitro. Methods 6,7-Dimethoxy-4-chloroquinoline, 6-chloro-7-deazapurinepurine, and 4-chloro-7-azaindole were used as starting material to synthesize the target compounds 3a-5c by substitution, reduction and condensation reactions. The antitumor activities of the compounds against GTL-16 cells were investigated by methyl thiazolyl tetrazoliym (MTT) assay. Results Nine novel benzamide compounds were synthesized. The structures were characterized by MS, 1H-NMR, and 13C-NMR techniques. All of the compounds had different extents potency of antitumor activities against GTL-16 cells. Especially the IC50 value of the compound 3c was 411 nmol/L. Conclusion Benzamide compounds have good antitumor activities against GTL-16 cells, which could be a valuable candidate for further development.
出处 《现代药物与临床》 CAS 2016年第9期1313-1318,共6页 Drugs & Clinic
关键词 苯酰胺类 c-Met激酶抑制剂 合成 GTL-16细胞 抑制 benzamide c-Met inhibitor synthsis GTL-16 cell inhibitation
  • 相关文献

参考文献12

  • 1Jung K H, Park B H, Hong S S. Progress in cancer therapy targeting c-Met signaling pathway [J]. Arch Pharm Res, 2012, 35(4): 595-604.
  • 2李永文(综述),刘红雨(审校),陈军(审校).肺癌细胞中HGF/c-Met信号通路的异常调控及其靶向药物研究进展[J].中国肺癌杂志,2014,17(8):625-634. 被引量:9
  • 3Garajovli I, Giovannetti E, Biasco G, et al. c-Met as a target for personalized therapy [J]. Transl Oncogenomics, 2015, 7(Suppl 1): 13-31.
  • 4Timofeevski S L, Mctigue M A, Ryan K, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors [J]. Biochemistry, 2009, 48(23): 5339-5349.
  • 5Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3 [J]. Clin CancerRes, 2011, 17(22): 7127-7138.
  • 6Nakagawa T, Tohyama O, Yamaguchi A, et al. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models [J]. Cancer Sci, 2010, 101(1): 210-215.
  • 7Kwon Y, Smith B D, Zhou Y, et al. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment [J]. Oncogene, 2013, 34(2): 144-153.
  • 8Qi B, Tao H, Wu D, et al. Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors [J]. Arch Pharm (Weinheim), 2013, 346(8): 596-609.
  • 9倪春燕,张虞婷,赵育,朱俐.吡唑并[1,5-a]嘧啶类c-Met激酶抑制剂的合成及生物活性研究[J].有机化学,2012,32(12):2294-2299. 被引量:2
  • 10Li S, Jiang R, Qin M, et al. Synthesis and antitumor activity of novel 4-(2-fluorophenoxy)quinoline derivatives bearing the 4-oxo-l,4-dihydroquinoline-3-carboxamide moiety [J]. Arch Pharm (Weinheim). 2013, 346(7): 521-533.

二级参考文献18

  • 1Toshiyuki Otsuka,Norio Horiguchi,Daisuke Kanda,Takashi Kosone,Yuichi Yamazaki,Kazuhisa Yuasa,Naondo Sohara,Satoru Kakizaki,Ken Sato,Hitoshi Takagi,Glenn Merlino,Masatomo Mori.Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice[J].World Journal of Gastroenterology,2005,11(47):7444-7449. 被引量:2
  • 2Jeffers, M.; Schmidt, L.; Nakaigawa, N.; Webb, C. P.; Weirich, G.; Kishida, T.; Zbar, B.; Vande Woude, G. F. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 11445.
  • 3Ferracini, R.; Olivero, M.; Di Renzo, M. F.; Martano, M.; De Giovanni, C.; Nanni, P.; Basso, G.; Scotlandi, K.; Lollini, P. L.; Comoglio, P. M. Oncogene 1996, 12, 1697.
  • 4Canadas, 1.; Rojo, F.; Arumi-Uria, M.; Rovira, A.; Albanell, J.; Arriola, E. Clin. Transl. Oneol. 2010, 12, 253.
  • 5Cecchi, F.; Rabe, D. C.; Bottaro, D. P. Eur. J. Cancer 2010, 46,1260.
  • 6Stellrecht, C. M.; Gandhi, V. CancerLe#. 2009, 280, 1.
  • 7Peruzzi, B.; Bottaro, D. P. Clin. CancerRes. 2006, 12, 3657.
  • 8Liu, X.; Newton, R. C.; Scherle, P. A. Trends Mol. Med. 2010, 16, 37.
  • 9Bode, C. M.; Boezio, A. A.; Albrecht, B. K.; Bellon, S. F.; Berry, L.; Broome, M. A.; Choquette, D.; Dussault, I.; Lewis, R. T.; Lin, M. H.; Rex, K.; Whittington, D. A.; Yang, Y.; Harmange, J. C. Bioorg. Med. Chem. Lett. 2012, 22, 4089.
  • 10Underiner, T. L.; Herbertz, T.; Miknyoczki, S. J. Anticancer Agents Med. Chem. 2010, 10, 7.

共引文献9

同被引文献20

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部